320 related articles for article (PubMed ID: 11830545)
1. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.
Curnis F; Arrigoni G; Sacchi A; Fischetti L; Arap W; Pasqualini R; Corti A
Cancer Res; 2002 Feb; 62(3):867-74. PubMed ID: 11830545
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).
Curnis F; Sacchi A; Borgna L; Magni F; Gasparri A; Corti A
Nat Biotechnol; 2000 Nov; 18(11):1185-90. PubMed ID: 11062439
[TBL] [Abstract][Full Text] [Related]
3. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
4. Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.
Corti A; Ponzoni M
Ann N Y Acad Sci; 2004 Dec; 1028():104-12. PubMed ID: 15650236
[TBL] [Abstract][Full Text] [Related]
5. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.
Di Matteo P; Curnis F; Longhi R; Colombo G; Sacchi A; Crippa L; Protti MP; Ponzoni M; Toma S; Corti A
Mol Immunol; 2006 Apr; 43(10):1509-18. PubMed ID: 16337683
[TBL] [Abstract][Full Text] [Related]
7. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
8. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
9. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.
Curnis F; Sacchi A; Gasparri A; Longhi R; Bachi A; Doglioni C; Bordignon C; Traversari C; Rizzardi GP; Corti A
Cancer Res; 2008 Sep; 68(17):7073-82. PubMed ID: 18757422
[TBL] [Abstract][Full Text] [Related]
10. In vitro targeted killing of human endothelial cells by co-incubation of human serum and NGR peptide conjugated human albumin protein bearing alpha (1-3) galactose epitopes.
Holle L; Song W; Hicks L; Holle E; Holmes L; Wei Y; Li J; Wagner T; Yu X
Oncol Rep; 2004 Mar; 11(3):613-6. PubMed ID: 14767511
[TBL] [Abstract][Full Text] [Related]
11. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.
Dunne M; Zheng J; Rosenblat J; Jaffray DA; Allen C
J Control Release; 2011 Sep; 154(3):298-305. PubMed ID: 21640146
[TBL] [Abstract][Full Text] [Related]
12. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
13. cNGR: a novel homing sequence for CD13/APN targeted molecular imaging of murine cardiac angiogenesis in vivo.
Buehler A; van Zandvoort MA; Stelt BJ; Hackeng TM; Schrans-Stassen BH; Bennaghmouch A; Hofstra L; Cleutjens JP; Duijvestijn A; Smeets MB; de Kleijn DP; Post MJ; de Muinck ED
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2681-7. PubMed ID: 16990557
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms.
Curnis F; Gasparri A; Sacchi A; Cattaneo A; Magni F; Corti A
Cancer Res; 2005 Apr; 65(7):2906-13. PubMed ID: 15805293
[TBL] [Abstract][Full Text] [Related]
15. NGR peptide ligands for targeting CD13/APN identified through peptide array screening resemble fibronectin sequences.
Soudy R; Ahmed S; Kaur K
ACS Comb Sci; 2012 Nov; 14(11):590-9. PubMed ID: 23030271
[TBL] [Abstract][Full Text] [Related]
16. Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
Takara K; Hatakeyama H; Kibria G; Ohga N; Hida K; Harashima H
J Control Release; 2012 Aug; 162(1):225-32. PubMed ID: 22728515
[TBL] [Abstract][Full Text] [Related]
17. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells.
Wang X; Wang Y; Chen X; Wang J; Zhang X; Zhang Q
J Control Release; 2009 Oct; 139(1):56-62. PubMed ID: 19470394
[TBL] [Abstract][Full Text] [Related]
18. Strategies for improving the anti-neoplastic activity of TNF by tumor targeting.
Corti A
Methods Mol Med; 2004; 98():247-64. PubMed ID: 15064445
[TBL] [Abstract][Full Text] [Related]
19. NGR enhanced the anti-angiogenic activity of tum-5.
Meng J; Ma N; Yan Z; Han W; Zhang Y
J Biochem; 2006 Aug; 140(2):299-304. PubMed ID: 16845126
[TBL] [Abstract][Full Text] [Related]
20. An antimicrobial peptide containing NGR motif has potent antitumor activity against CD13+ and CD13- tumor cells.
Zhang Z; Hou L; Feng L; Huang S; Luo M; Shao S; Zhang X; Gu S; Zhao X
Tumour Biol; 2015 Sep; 36(10):8167-75. PubMed ID: 25990455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
